Hospital Universitario Y Politecnico La Fe

The research portfolio at Hospital Universitario Y Politecnico La Fe in Valencia is strongly centered on Medical Oncology, with a major focus on neoplasms and a wide range of solid tumors and hematologic malignancies. Studies here are largely aimed at testing new cancer therapies, comparing treatment strategies, and improving outcomes for patients with advanced or hard-to-treat disease.

• Advanced lung cancer, especially non-small cell lung cancer and small cell lung cancer, with trials evaluating new targeted and immunotherapy-based treatments
• Blood cancers such as acute myeloid leukemia, myelodysplastic syndromes, multiple myeloma, and lymphomas, including studies of novel treatment combinations and relapse management
• Breast cancer, ovarian cancer, prostate cancer, and colorectal cancer, with research focused on improving disease control and extending survival
• Early-phase oncology research in advanced solid tumors, designed to explore promising therapies for patients with limited standard options

The site’s oncology trials also include work on treatment effectiveness, maintenance approaches, and personalized care for patients with specific molecular features, reflecting a broad and active cancer research program.

A substantial part of the clinical trial activity at this site covers hematologic diseases and cellular therapy. Research includes aggressive and relapsed blood cancers, as well as studies supporting transplant-related care and immune-based treatments. The overall goal is to improve remission rates, reduce relapse, and refine post-transplant management.

• Acute leukemias, including acute lymphoblastic leukemia and acute myeloid leukemia, with trials aimed at better disease control and survival
• Myelodysplastic syndromes and related disorders, including studies focused on anemia and lower-risk disease management
• Multiple myeloma and lymphomas, with investigations of new combinations for relapsed or refractory disease
• Transplant-associated complications, including graft-versus-host disease and infection prevention after stem cell transplantation

These studies highlight the strong role of Hospital Universitario Y Politecnico La Fe in advancing blood cancer care and post-transplant treatment strategies.

Clinical research in digestive system diseases and immune-mediated disorders is another major theme at the site. Trials address chronic inflammatory bowel disease, liver conditions, and related complications, with an emphasis on improving symptom control, long-term disease management, and quality of life.

• Crohn’s disease and ulcerative colitis, including studies of new therapies for moderate to severe disease
• Primary biliary cholangitis, non-alcoholic steatohepatitis, and other liver diseases, with research focused on symptom relief and disease progression
• Inflammatory bowel diseases and related intestinal disorders, aimed at improving disease control
• Transplant-related liver care and other gastrointestinal complications, supporting better recovery and long-term outcomes

This area reflects a broad effort to test new approaches for chronic digestive and liver conditions that can be difficult to manage with standard care alone.

The site also supports a wide range of trials in nervous system diseases, including neurodegenerative diseases, seizure disorders, and rare neuromuscular conditions. Research is directed toward slowing progression, improving symptoms, and identifying better treatment options for patients with limited alternatives.

• Alzheimer’s disease, Parkinson’s disease, and other dementias, with studies aimed at improving diagnosis and disease management
• Multiple sclerosis, including relapsing and progressive forms, with trials testing therapies to reduce disease activity
• Amyotrophic lateral sclerosis, spinal muscular atrophy, and muscular dystrophies, focusing on symptom control and functional preservation
• Epilepsy, migraine, and other neurological symptom disorders, with research designed to improve control and reduce burden

These studies show a strong commitment to both common and rare neurological diseases, combining treatment development with long-term patient support.

Another active research area includes immune system diseases, rheumatologic disorders, and skin and connective tissue diseases. Trials here often seek to improve control of chronic inflammation, reduce flare-ups, and support safer long-term treatment strategies.

• Rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis, with studies focused on disease activity and treatment withdrawal strategies
• Systemic lupus erythematosus and lupus nephritis, aimed at better control of severe autoimmune disease
• Atopic dermatitis, hidradenitis suppurativa, and psoriasis, with research testing new options for chronic inflammatory skin disease
• Myasthenia gravis and other immune-mediated conditions, exploring therapies that may improve daily function

At Hospital Universitario Y Politecnico La Fe, these trials support a broader effort to make treatment more effective and more tailored for chronic inflammatory conditions.

Clinical trials in cardiovascular diseases, respiratory tract diseases, and nutritional and metabolic diseases add further depth to the site’s portfolio. Many of these studies focus on high-risk patients and aim to improve prevention, symptom control, and long-term outcomes.

• Heart failure, cardiomyopathy, and vascular disease, with research looking at better treatment effectiveness and risk reduction
• Pulmonary hypertension, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis, aimed at improving breathing-related health
• Type 2 diabetes, obesity, and metabolic liver disease, with studies evaluating long-term disease management
• Kidney disease and related complications, including work on patients with advanced chronic conditions

These trials show that the site’s research extends beyond oncology, covering major chronic diseases that affect overall health and quality of life.